Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …

The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …

Colorectal cancer is a leading cause of cancer related deaths worldwide. One of the
hallmarks of cancer and a fundamental trait of virtually all gastrointestinal cancers is …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

In many areas of oncology, we lack sensitive tools to track low-burden disease. Although cell-
free DNA (cfDNA) shows promise in detecting cancer mutations, we found that the …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Background A high percentage of patients diagnosed with localized colon cancer (CC) will
relapse after curative treatment. Although pathological staging currently guides our …

Background Precise methods for postoperative risk stratification to guide the administration
of adjuvant chemotherapy (ACT) in localized colorectal cancer (CRC) are still lacking. Here …